サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1701276

米国の脳腫瘍の市場規模、シェア、動向分析レポート：腫瘍タイプ別、治療タイプ別、セグメント予測、2025年～2034年

U.S. Brain Tumor Market Size, Share & Trends Analysis Report By Tumor Type (Malignant, Non-malignant), By Treatment Type (Surgery, Radiation Therapy, Interventional Device-Based Procedures, Chemotherapy), And Segment Forecasts, 2025 - 2034

出版日
ページ情報
英文 110 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
米国の脳腫瘍の市場規模、シェア、動向分析レポート：腫瘍タイプ別、治療タイプ別、セグメント予測、2025年～2034年
出版日: 2025年03月12日
発行: Grand View Research
ページ情報: 英文 110 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の脳腫瘍市場の成長と動向：

Grand View Research社の最新レポートによると、米国の脳腫瘍市場は2034年までに43億5,000万米ドルに達し、2025年から2034年までのCAGRは9.87％で成長すると予測されています。

例えば、National Brain Tumor Societyの報告書によると、推定100万人の米国人が現在原発性脳腫瘍を患っており、効果的な治療法を必要としている患者層が相当数いることが浮き彫りになっています。これらの腫瘍のうち、2023年には約72％が良性、28％が悪性に分類され、多様な治療ニーズとアプローチがあることを示しています。さらに、同じ情報源によると、非悪性髄膜腫は一次非悪性脳腫瘍の中で最も多いタイプであり、全脳腫瘍の約39.7％、全非悪性腫瘍の55.4％を占める。

官民両部門からの資金提供や投資の増加も、市場拡大の原動力となっており、市場成長をさらに後押ししています。さらに、標的療法、免疫療法、手術手技の進歩を含む治療選択肢の継続的な革新が、市場拡大において重要な役割を果たしています。精密医療におけるブレークスルーは、より個別化された治療計画を可能にし、患者の転帰を向上させ、投資を惹きつけています。

市場の成長ステージは高く、そのペースは加速しています。米国の脳腫瘍市場は、脳腫瘍の有病率の上昇に加え、より優れた診断ツール、標的療法などの治療法の革新、政府、非営利団体、民間部門からの脳腫瘍研究への多額の資金提供、手術、放射線療法、化学療法などの幅広い治療選択肢の利用可能性などにより、成長を特徴としています。

米国の脳腫瘍市場レポートハイライト

  • 腫瘍タイプ別では、脳腫瘍の有病率の上昇、膠芽腫および高悪性度悪性脳腫瘍の発生率の増加により、2024年には悪性セグメントが最大の売上シェアを占めました。
  • 膠芽腫を含む悪性脳腫瘍は、通常、手術、化学療法、放射線療法を組み合わせた積極的な治療アプローチを必要とすることが多いです。
  • 治療タイプに基づくと、いくつかの説得力のある要因により、2024年には外科手術セグメントが最大の市場シェアを占めました。第一に、外科的介入は多くタイプの脳腫瘍、特に膠芽腫のような悪性腫瘍を管理するための主要なアプローチであり続けています。開頭術や腫瘍切除術を含む外科的処置は、腫瘍を可能な限り除去することを目的としており、これにより脳への圧迫を緩和し、症状を緩和し、全体的な患者の転帰を改善することができます。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 米国の脳腫瘍市場の変数、動向、範囲

  • 市場系統の見通し
    • 親市場の見通し
    • 関連/付随市場の見通し
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • 米国の脳腫瘍市場分析ツール
    • 業界分析- ポーターのファイブフォース分析
    • PESTEL分析

第4章 米国の脳腫瘍市場：腫瘍タイプの推定・動向分析

  • 定義と範囲
  • 腫瘍タイプの市場シェア、2024年と2034年
  • セグメントダッシュボード
  • 米国の脳腫瘍市場：腫瘍タイプ別展望
  • 市場規模と予測および動向分析、2024年～2034年（腫瘍タイプ別治療を受ける患者数）
    • 悪性
    • 非悪性

第5章 米国の脳腫瘍市場：治療タイプの推定・動向分析

  • 定義と範囲
  • 治療タイプの市場シェア、2024年と2030年
  • セグメントダッシュボード
  • 米国の脳腫瘍市場：治療タイプ別展望
  • 悪性腫瘍治療タイプの市場規模と予測および動向分析、2024年～2034年
    • 手術
    • 放射線治療
    • 介入デバイスベースの手順
    • 化学療法
    • 標的療法
    • 腫瘍治療場（TTF）
    • レーザー組織内温熱療法（LITT）
    • 外科的標的放射線療法
    • カテーテルを用いた超音波熱凝固術
    • 集束超音波（FUS）
    • 低強度焦点式超音波（LIFU）
  • 非悪性腫瘍治療タイプの市場規模と予測および動向分析、2024年～2034年
    • 手術
    • 放射線治療
    • その他のモニタリングデバイス

第6章 競合情勢

  • 主要市場参入企業による最近の動向と影響分析
  • 企業/競合の分類
    • イノベーター
  • ベンダー情勢
    • 主要販売代理店およびチャネルパートナーのリスト
    • 主要顧客
    • 主要企業の市場シェア分析（2024年）
    • GT Medical Technologies, Inc.
    • Novocure
    • ZAP Surgical Systems, Inc.
    • Aesculap, Inc.-a B. Braun company
    • Accuray Incorporated
    • Carthera
    • Alpheus Medical Inc.
    • Alpha Tau Medical Ltd
    • Elekta
    • IMRIS Inc.
    • Medtronic
    • Monteris
    • Openwater
    • Acoustic MedSystems, Inc.
    • NaviFUS Corp
    • Insightec
    • Varian Medical Systems, Inc.（Siemens Healthineers）
    • RefleXion
    • MagnetTx Oncology Solutions Ltd.
    • NICO Corporation（Stryker）
    • Terumo Interventional Systems
    • Boston Scientific Corporation
    • Koninklijke Philips NV
    • IBA Worldwide
図表

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 U.S. Brain Tumor market, by Treatment Type 2024 - 2034 (USD Million)
  • Table 4 U.S. Brain Tumor market, by Tumor Type 2024 - 2034 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. brain tumor market: Market snapshot
  • Fig. 9 U.S. brain tumor market: Market segmentation
  • Fig. 10 U.S. brain tumor market: Strategy framework
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 U.S. brain tumor market driver impact
  • Fig. 14 U.S. brain tumor market restraint impact
  • Fig. 15 U.S. brain tumor market porter's five forces analysis
  • Fig. 16 U.S. brain tumor market PESTEL analysis
  • Fig. 17 U.S. brain tumor market segment dashboard
  • Fig. 18 U.S. brain tumor market: Tumor type movement Analysis
  • Fig. 19 Malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 20 Non-malignant brain tumor market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 21 U.S. brain tumor market: Treatment type (malignant) movement Analysis
  • Fig. 22 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 23 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 24 Interventional device-based procedures market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 25 Chemotherapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 26 Targeted therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 27 Tumor Treating Fields (TTF) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 28 Laser Interstitial Thermal Therapy (LITT) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 29 Surgically targeted radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 30 Catheter-based ultrasound thermal ablation market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 31 Focused Ultrasound (FUS) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 32 Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 33 U.S. brain tumor market: Treatment type (non-malignant) movement Analysis
  • Fig. 34 Surgery market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 35 Radiation therapy market estimates and forecast, 2024 - 2034 (USD Million)
  • Fig. 36 Other monitoring devices market estimates and forecast, 2024 - 2034 (USD Million)
目次
Product Code: GVR-4-68040-534-5

U.S. Brain Tumor Market Growth & Trends:

The U.S. brain tumor market is anticipated to reach USD 4.35 billion by 2034, growing at a CAGR of 9.87% from 2025 to 2034, according to a new report by Grand View Research, Inc. The market growth is primarily driven by the increasing prevalence of brain cancer and rising number of brain tumor diagnoses in the U.S. For instance, according to the National Brain Tumor Society report, an estimated one million Americans are currently living with a primary brain tumor, highlighting a substantial patient population in need of effective treatment options. Among these tumors, approximately 72% were classified as benign, while 28% were malignant in 2023, indicating a diverse range of treatment needs and approaches. Furthermore, according to the same source, non-malignant meningiomas represent the most prevalent type of primary non-malignant brain tumors, comprising approximately 39.7% of all brain tumors and 55.4% of all non-malignant tumors.

Increasing funding and investments from both public and private sectors are also driving market expansion and further fueling market growth. Furthermore, continued innovation in treatment options, including targeted therapies, immunotherapies, and advancements in surgical techniques is playing a crucial role in market expansion. Breakthroughs in precision medicine allow for more personalized treatment plans, which enhance patient outcomes and attract investment.

The market growth stage is high, and the pace of the market growth is accelerating. The U.S. brain tumor market is characterized by growth owing to the rising prevalence of brain tumors, along with better diagnostic tools, innovations in treatment modalities, such as targeted therapies, substantial funding for brain tumor research from government, non-profits, and private sectors, and availability of a wide range of treatment options, including surgery, radiation therapy, and chemotherapy, among others.

U.S. Brain Tumor Market Report Highlights:

  • Based on tumor type, the malignant segment accounted for the largest revenue share in 2024 driven by the rising prevalence of brain cancer and increasing incidence of glioblastoma and high-grade malignant brain tumors
  • Malignant brain tumors, including glioblastomas, often require aggressive treatment approaches, which typically involve a combination of surgery, chemotherapy, and radiation therapy
  • Based on treatment type, the surgery segment accounted for the largest market share in 2024 due to several compelling factors. Firstly, surgical intervention remains the primary approach for managing many types of brain tumors, particularly malignant tumors such as glioblastomas. Surgical procedures, including craniotomy and tumor resection, aim to remove as much of the tumor as possible, which can relieve pressure on the brain, alleviate symptoms, and improve overall patient outcomes

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary sources
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research in the U.S.
  • 1.4. Information or Data Analysis
    • 1.4.1. Data analysis models
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity flow analysis (Model 1)
      • 1.6.1.1. Approach 1: Commodity flow approach
    • 1.6.2. Volume price analysis (Model 2)
      • 1.6.2.1. Approach 2: Volume price analysis
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Tumor Type outlook
    • 2.2.2. Treatment Type outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Brain Tumor Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Rising prevalence of primary and secondary brain tumors
      • 3.2.1.2. Innovations in diagnostic imaging, surgical techniques (such as advanced neurosurgery), and therapeutic modalities (such as targeted therapies, immunotherapies, and radiotherapy)
      • 3.2.1.3. Increasing awareness and early diagnosis of brain tumor
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Side effects and complications associated with brain tumor treatrment
    • 3.2.3. Market opportunity analysis
      • 3.2.3.1. Increasing number of clinical trials
      • 3.2.3.2. Rising fundings and investments from both public and private sectors in research and development activities
    • 3.2.4. Market challenge analysis
      • 3.2.4.1. Product recalls
      • 3.2.4.2. Stringent regulations
  • 3.3. U.S. Brain tumor Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Brain Tumor Market: Tumor Type Estimates & Trend Analysis

  • 4.1. Definitions and Scope
  • 4.2. Tumor Type Market Share, 2024 & 2034
  • 4.3. Segment Dashboard
  • 4.4. U.S. Brain Tumor Market by Tumor Type Outlook
  • 4.5. Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.1. Malignant
      • 4.5.1.1. Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.2. Glioblastomas
        • 4.5.1.2.1. Glioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.3. Medulloblastomas
        • 4.5.1.3.1. Medulloblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.4. Astrocytomas
        • 4.5.1.4.1. Astrocytomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.5. Ependymomas
        • 4.5.1.5.1. Ependymomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.1.6. Others
        • 4.5.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
    • 4.5.2. Non-Malignant
      • 4.5.2.1. Non-Malignant market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.2. Meningiomas
        • 4.5.2.2.1. Meningiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.3. Pituitary Adenomas
        • 4.5.2.3.1. Pituitary Adenomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.4. Craniopharyngiomas
        • 4.5.2.4.1. Craniopharyngiomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.5. Hemangioblastomas
        • 4.5.2.5.1. Hemangioblastomas market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 4.5.2.6. Others
        • 4.5.2.6.1. Others market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)

Chapter 5. U.S. Brain Tumor Market: Treatment Type Estimates & Trend Analysis

  • 5.1. Definitions and Scope
  • 5.2. Treatment Type Market Share, 2024 & 2030
  • 5.3. Segment Dashboard
  • 5.4. U.S. Brain Tumor Market by Treatment Type Outlook
  • 5.5. Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
    • 5.5.1. Surgery
      • 5.5.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 5.5.1.2. Neurosurgical Instruments
        • 5.5.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.3. Robotic Surgery Systems
        • 5.5.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.4. Interventional Device-Based Procedures
        • 5.5.1.4.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.5. Endoscopes
        • 5.5.1.5.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.6. Intraoperative Imaging Systems
        • 5.5.1.6.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.1.7. Others
        • 5.5.1.7.1. Others market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.2. Radiation Therapy
      • 5.5.2.1. Radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
        • 5.5.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.2.2.2. Linear Accelerators (LINAC)
          • 5.5.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.2.2.3. Gamma Knife Systems
          • 5.5.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.2.2.4. Proton radiosurgery
          • 5.5.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.2.3. Internal radiation/Brachytherapy devices
        • 5.5.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.3. Interventional Device-Based Procedures
      • 5.5.3.1. Interventional device-based procedures market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.2. Embolization Devices
        • 5.5.3.2.1. Embolization devices market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.3.2.2. Liquid Embolic Agents
          • 5.5.3.2.2.1. Liquid embolic agents market estimates and forecast 2024 to 2034 (USD Million)
        • 5.5.3.2.3. Microspheres
          • 5.5.3.2.3.1. Microspheres market estimates and forecast 2024 to 2034 (USD Million)
      • 5.5.3.3. Tumor Ablation Devices
        • 5.5.3.3.1. Tumor ablation devices market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.4. Chemotherapy
      • 5.5.4.1. Chemotherapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.5. Targeted Therapy
      • 5.5.5.1. Targeted therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.6. Tumor Treating Fields (TTF)
      • 5.5.6.1. Tumor Treating Fields (TTF) market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.7. Laser Interstitial Thermal Therapy (LITT)
      • 5.5.7.1. Laser Interstitial Thermal Therapy (LITT) market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.8. Surgically Targeted Radiation Therapy
      • 5.5.8.1. Surgically targeted radiation therapy market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.9. Catheter-Based Ultrasound Thermal Ablation
      • 5.5.9.1. Catheter-based ultrasound thermal ablation market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.10. Focused Ultrasound (FUS)
      • 5.5.10.1. Focused Ultrasound (FUS) market estimates and forecast 2024 to 2034 (USD Million)
    • 5.5.11. Low-Intensity Focused Ultrasound (LIFU)
      • 5.5.11.1. Low-Intensity Focused Ultrasound (LIFU) market estimates and forecast 2024 to 2034 (USD Million)
  • 5.6. Non-Malignant Tumor Treatment Type Market Size & Forecasts and Trend Analyses, 2024 to 2034 (Number of Patients per Treatment), USD Million in Terms of Number of Patients per Treatment, Volume (Unit)
    • 5.6.1. Surgery
      • 5.6.1.1. Surgery market estimates and forecast 2024 to 2034 (USD Million), (Number of Patients Undergo Treatment Per Tumor Type)
      • 5.6.1.2. Neurosurgical Instruments
        • 5.6.1.2.1. Neurosurgical instruments market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.2. Blade, Knife, Cutter & Scissors
          • 5.6.1.2.2.1. Blade, knife, cutter & scissors market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.3. Dissector
          • 5.6.1.2.3.1. Dissector market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.4. Drill & Perforator
          • 5.6.1.2.4.1. Drill & perforator market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.1.2.5. Others
          • 5.6.1.2.5.1. Others market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.3. Robotic Surgery Systems
        • 5.6.1.3.1. Robotic surgery systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.4. Endoscopes
        • 5.6.1.4.1. Endoscopes market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.5. Intraoperative Imaging Systems
        • 5.6.1.5.1. Intraoperative imaging systems market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.1.6. Others
        • 5.6.1.6.1. Others market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.2. Radiation Therapy
      • 5.6.2.1. Radiation Therapy market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.2. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices
        • 5.6.2.2.1. External Beam Radiation Therapy (EBRT)/Stereotactic Radiosurgery (SRS) Devices market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.2.2.2. Linear Accelerators (LINAC)
          • 5.6.2.2.2.1. Linear Accelerators (LINAC) market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.2.2.3. Gamma Knife Systems
          • 5.6.2.2.3.1. Gamma knife systems market estimates and forecast 2024 to 2034 (USD Million)
        • 5.6.2.2.4. Proton radiosurgery
          • 5.6.2.2.4.1. Proton radiosurgery market estimates and forecast 2024 to 2034 (USD Million)
      • 5.6.2.3. Internal radiation/Brachytherapy Devices
        • 5.6.2.3.1. Internal radiation/brachytherapy devices market estimates and forecast 2024 to 2034 (USD Million)
    • 5.6.3. Other Monitoring Devices
      • 5.6.3.1. Other monitoring devices market estimates and forecast 2024 to 2034 (USD Million)

Chapter 6. Competitive Landscape

  • 6.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 6.2. Company/Competition Categorization
    • 6.2.1. Innovators
  • 6.3. Vendor Landscape
    • 6.3.1. List of key distributors and channel partners
    • 6.3.2. Key customers
    • 6.3.3. Key company market share analysis, 2024
    • 6.3.4. GT Medical Technologies, Inc.
      • 6.3.4.1. Company overview
      • 6.3.4.2. Financial performance
      • 6.3.4.3. Product benchmarking
      • 6.3.4.4. Strategic initiatives
    • 6.3.5. Novocure
      • 6.3.5.1. Company overview
      • 6.3.5.2. Financial performance
      • 6.3.5.3. Product benchmarking
      • 6.3.5.4. Strategic initiatives
    • 6.3.6. ZAP Surgical Systems, Inc.
      • 6.3.6.1. Company overview
      • 6.3.6.2. Financial performance
      • 6.3.6.3. Product benchmarking
      • 6.3.6.4. Strategic initiatives
    • 6.3.7. Aesculap, Inc. - a B. Braun company
      • 6.3.7.1. Company overview
      • 6.3.7.2. Financial performance
      • 6.3.7.3. Product benchmarking
      • 6.3.7.4. Strategic initiatives
    • 6.3.8. Accuray Incorporated
      • 6.3.8.1. Company overview
      • 6.3.8.2. Financial performance
      • 6.3.8.3. Product benchmarking
      • 6.3.8.4. Strategic initiatives
    • 6.3.9. Carthera
      • 6.3.9.1. Company overview
      • 6.3.9.2. Financial performance
      • 6.3.9.3. Product benchmarking
      • 6.3.9.4. Strategic initiatives
    • 6.3.10. Alpheus Medical Inc.
      • 6.3.10.1. Company overview
      • 6.3.10.2. Financial performance
      • 6.3.10.3. Product benchmarking
      • 6.3.10.4. Strategic initiatives
    • 6.3.11. Alpha Tau Medical Ltd
      • 6.3.11.1. Company overview
      • 6.3.11.2. Financial performance
      • 6.3.11.3. Product benchmarking
      • 6.3.11.4. Strategic initiatives
    • 6.3.12. Elekta
      • 6.3.12.1. Company overview
      • 6.3.12.2. Financial performance
      • 6.3.12.3. Product benchmarking
      • 6.3.12.4. Strategic initiatives
    • 6.3.13. IMRIS Inc.
      • 6.3.13.1. Company overview
      • 6.3.13.2. Financial performance
      • 6.3.13.3. Product benchmarking
      • 6.3.13.4. Strategic initiatives
    • 6.3.14. Medtronic
      • 6.3.14.1. Company overview
      • 6.3.14.2. Financial performance
      • 6.3.14.3. Product benchmarking
      • 6.3.14.4. Strategic initiatives
    • 6.3.15. Monteris
      • 6.3.15.1. Company overview
      • 6.3.15.2. Financial performance
      • 6.3.15.3. Product benchmarking
      • 6.3.15.4. Strategic initiatives
    • 6.3.16. Openwater
      • 6.3.16.1. Company overview
      • 6.3.16.2. Financial performance
      • 6.3.16.3. Product benchmarking
      • 6.3.16.4. Strategic initiatives
    • 6.3.17. Acoustic MedSystems, Inc.
      • 6.3.17.1. Company overview
      • 6.3.17.2. Financial performance
      • 6.3.17.3. Product benchmarking
      • 6.3.17.4. Strategic initiatives
    • 6.3.18. NaviFUS Corp
      • 6.3.18.1. Company overview
      • 6.3.18.2. Financial performance
      • 6.3.18.3. Product benchmarking
      • 6.3.18.4. Strategic initiatives
    • 6.3.19. Insightec
      • 6.3.19.1. Company overview
      • 6.3.19.2. Financial performance
      • 6.3.19.3. Product benchmarking
      • 6.3.19.4. Strategic initiatives
    • 6.3.20. Varian Medical Systems, Inc. (Siemens Healthineers)
      • 6.3.20.1. Company overview
      • 6.3.20.2. Financial performance
      • 6.3.20.3. Product benchmarking
      • 6.3.20.4. Strategic initiatives
    • 6.3.21. RefleXion
      • 6.3.21.1. Company overview
      • 6.3.21.2. Financial performance
      • 6.3.21.3. Product benchmarking
      • 6.3.21.4. Strategic initiatives
    • 6.3.22. MagnetTx Oncology Solutions Ltd.
      • 6.3.22.1. Company overview
      • 6.3.22.2. Financial performance
      • 6.3.22.3. Product benchmarking
      • 6.3.22.4. Strategic initiatives
    • 6.3.23. NICO Corporation (Stryker)
      • 6.3.23.1. Company overview
      • 6.3.23.2. Financial performance
      • 6.3.23.3. Product benchmarking
      • 6.3.23.4. Strategic initiatives
    • 6.3.24. Terumo Interventional Systems
      • 6.3.24.1. Company overview
      • 6.3.24.2. Financial performance
      • 6.3.24.3. Product benchmarking
      • 6.3.24.4. Strategic initiatives
    • 6.3.25. Boston Scientific Corporation
      • 6.3.25.1. Company overview
      • 6.3.25.2. Financial performance
      • 6.3.25.3. Product benchmarking
      • 6.3.25.4. Strategic initiatives
    • 6.3.26. Koninklijke Philips N.V.
      • 6.3.26.1. Company overview
      • 6.3.26.2. Financial performance
      • 6.3.26.3. Product benchmarking
      • 6.3.26.4. Strategic initiatives
    • 6.3.27. IBA Worldwide
      • 6.3.27.1. Company overview
      • 6.3.27.2. Financial performance
      • 6.3.27.3. Product benchmarking
      • 6.3.27.4. Strategic initiatives